Guideline for the management of <i>Clostridioides difficile</i> infection in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2024 update.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 38680517.
- Also identified by DOI 10.1016/j.eclinm.2024.102604 and PMC identifier 11046252.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Our objective was to update a clinical practice guideline for the prevention and treatment of <i>Clostridioides difficile</i> infection (CDI) in pediatric patients with cancer and hematopoietic cell transplantation recipients. We reconvened an international multi-disciplinary panel. A systematic review of randomized controlled trials (RCTs) for the prevention or treatment of CDI in any population was updated and identified 31 new RCTs. Strong recommendations were made to use either oral metronidazole or oral vancomycin for non-severe CDI treatment, and to use either oral vancomycin or oral fidaxomicin for severe CDI. A strong recommendation that fecal microbiota transplantation should not be routinely used to treat CDI was also made. The panel made two new good practice statements to follow infection control practices including isolation in patients experiencing CDI, and to minimize systemic antibacterial administration where feasible, especially in patients who have experienced CDI.